Photocure ASA (OSL:PHO)

Norway flag Norway · Delayed Price · Currency is NOK
52.80
-0.20 (-0.38%)
Jun 24, 2025, 4:25 PM CET
-14.15%
Market Cap 1.41B
Revenue (ttm) 532.69M
Net Income (ttm) 2.14M
Shares Out 26.61M
EPS (ttm) 0.08
PE Ratio 659.57
Forward PE 148.44
Dividend n/a
Ex-Dividend Date n/a
Volume 52,462
Average Volume 39,988
Open 52.80
Previous Close 53.00
Day's Range 52.50 - 53.70
52-Week Range 47.00 - 65.60
Beta 0.61
RSI 61.52
Earnings Date Jul 30, 2025

About Photocure ASA

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreemen... [Read more]

Sector Healthcare
Founded 1993
Employees 101
Stock Exchange Oslo Børs
Ticker Symbol PHO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.